Xintela granted 1 million SEK from Vinnova


Lund, Sweden, May 8, 2020 - Xintela has been granted 1 million SEK from Vinnova in the call for ” Innovations in the wake of the crisis - Restructuring of society, operations and production in the wake of the corona epidemic.”. The grant concerns the funding of a preclinical study to evaluate Xintela's stem cells for the treatment of Covid-19 patients with the fatal disease condition ARDS (Acute Respiratory Distress Syndrome).

The project, which is partly financed by Vinnova, intends to evaluate safety and efficacy of Xintela's Mesenchymal Stem Cells (XSTEM®) in a preclinical model for ARDS, a disease condition that can affect Covid-19 patients. ARDS is a very serious and difficult-to-treat lung disease that requires oxygen therapy, often intensive care with a respirator, and leads to many deaths.

Xintela's stem cells will be tested in a validated ARDS model in collaboration with Associate Professor Sandra Lindstedt Ingemansson at the Department of Cardiothoracic Surgery and Transplantation at Skåne University Hospital in Lund. If the study is successful, the results will form the basis for an application to the Swedish Medical Products Agency to carry out clinical studies on Covid-19 patients with severe and deadly lung symptoms.

Xintela's application received a maximum grant in tough competition where 18 applications out of a total of 270 were approved. In total, SEK 10 million was available, with a maximum amount per application of SEK 1 million.

- To meet the huge need for a life-saving treatment for Covid-19 patients, we are expanding our development work on our selected and quality-assured stem cells. Stem cells have the potential to treat Covid-19 patients through the cells' anti-inflammatory and immunomodulatory effects by reducing the severe cytokine storm that affects the seriously ill patients. The fact that our project was approved in competition with a large number of applications is an exciting quality stamp for our efforts, says Xintela's CEO Evy Lundgren-Åkerlund.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication on the 8th of May 2020.

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Medicon Village
223 81 Lund, Sweden

About Xintela
Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00,


Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.

May 8, 2024
May 10, 2024
21st ESSKA Congress, Milan
Nov 30, 2023
Dec 2, 2023
3rd Regenerative Orthopaedic Summit by the Regenerative Medicine Orthopaedic Society (RMOS), Istanbul
Nov 21, 2023
Nov 23, 2023
43rd Orthopaedic World Congres by the International Society of Orthopaedic Surgery and Traumatology (SICOT), Cairo
Oct 10, 2023
Oct 12, 2023
2023 Cell & Gene Meeting on the Mesa, Carlsbad, October 10-12
Sep 9, 2023
Sep 12, 2023
- 17th world congress by the International Cartilage Regeneration & Joint Preservation Society (ICRS), Sitges/Barcelona
Jun 5, 2023
Jun 8, 2023
BIO International Convention, Boston
May 31, 2023
Jun 3, 2023
23rd European Congress of Rheumatology, by European Alliance of Associations for Rheumatology (EULAR), Milan
May 11, 2023
May 13, 2023
2nd Regenerative Orthopaedic Summit, Naples
May 12, 2023
May 13, 2023
10. Berliner Knorpelsymposium, Berlin
Apr 27, 2023
Apr 29, 2023
ICRS Focus Meeting on Allografts and synthetics on the frontstage, Nice
Apr 12, 2023
Apr 14, 2023
Cell & Gene Meeting on the Med 2023 Barcelona
Mar 17, 2023
Mar 20, 2023
OARSI world congress on osteoarthritis, Denver
Mar 16, 2023
BioStock Investor Meeting (broadcast online)
Mar 1, 2023
Mar 2, 2023
European Life Sciences CEO Forum (ELSF 2023) in Zürich, March 1-2, 2023
Feb 22, 2023
Redeye Theme: Regenerative Medicine / Cell Therapy, February 22, 2023
Jan 9, 2023
JPM Annual Healthcare Meeting 2023, San Francisco, January 9-12
Dec 1, 2022
1st Regenerative Orthopaedic Summit, Athens, December 1-3, 2022
Nov 29, 2022
BioStock Life Science Summit, Lund, November 29-30 2022
Nov 14, 2022
Investival Showcase, London, November 14, 2022
Nov 2, 2022
BioEurope (Digitalt), November 2-4, 2022
Oct 11, 2022
2022 Cell & Gene Meeting on the Mesa, Carlsbad, October 11-13
Oct 6, 2022
ICRS Focus Meeting, Bologna, October 6-7
Sep 28, 2022
Nordic Life Science Days, Malmö, September 28-29, 2022
Aug 30, 2022
2nd Integrin-Targeted Drug Development Summit, Boston, August 30 - September 1
Jun 13, 2022
Bio International Convention, San Diego, June 13-16
Jun 13, 2022
Småbolagsdagarna, Stockholm, June 13-15
March 30, 2023

Chairman Gregory Batcheller visited BioStock’s studio to tell us more about the company’s journey and business development.

March 16, 2023

CEO Evy Lundgren-Åkerlund presents the company at BioStock Investor Meeting on March 16, 2023.

November 30, 2022

CEO Evy Lundgren-Åkerlund presents the company at BioStock Life Science Fall Summit 2022 on November 30.

June 14, 2022

CEO Evy Lundgren-Åkerlund presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).

June 14, 2022

Targinta's CEO Per Norlén presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).

June 9, 2022

CEO Evy Lundgren-Åkerlund presents the company at BioStock Life Science Spring Summit 2022.

June 1, 2022

Watch the video interview with CEO Evy Lundgren-Åkerlund (in Swedish).

February 27, 2020

BioStock interview with Xintela's CMO and board member Sven Kili.

August 30, 2018

BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.

February 9, 2017

Dr. Marcus Keep comments on Xintelas glioblastoma project.

January 31, 2017

Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.

January 30, 2017

Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.

December 28, 2016

In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.

December 13, 2016

See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.

March 24, 2016

See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).

March 22, 2016

See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.

March 15, 2016

Investor presentation from Lund - Jan 27

January 14, 2016

Interview with Xintelas CEO

January 22, 2024
BioStock: Targinta’s CEO “Strong interest in ADCs in 2023”
June 1, 2023
DIs #InvestTalks - Xintela develops new generation stem cell products
May 30, 2023
BioStock: Xintela highlights the unique properties of XSTEM
May 2, 2023
BioStock: Xintela initiates last dose level in knee osteoarthritis study
March 22, 2023
BioStock: Targinta positions itself in the ADC field
July 6, 2022
BioStock: Xintela in clinical development
June 1, 2022
BioStock Studio: Xintela's CEO comments on the upcoming share issue
April 12, 2022
BioStock: Xintela's CEO on the potential in difficult-to-heal wounds
March 4, 2022
BioStock: Xintela presents plans for 2022 in its Q4 report
January 27, 2022
BioStock Studio: Targinta provides business update prior to spin-off
January 19, 2022
BioStock: Xintela advances to clinical phase in osteoarthritis and difficult-to-heal wounds 2022
October 12, 2021
BioStock: Professor Folke Sjöberg about XSTEM for treatment of venous leg ulcers.
November 9, 2020
BioStock: Xintela’s CEO comments on the positive patent notice
June 22, 2017
Xintela covered in GEN regarding its participation in multi-million, government funded initiative to form a...
March 2, 2017
Xintela covered in regarding that its stem cells are safe for use in horses
March 23, 2016
(Article in Swedish) Xintela tar behandling av ledskador och cancer till First North.
March 23, 2016
(Article in Swedish) Grundare av Xintela ser notering som viktig milstolpe
March 23, 2016
(Article in Swedish) Xintela covered in Life Science Sweden
February 24, 2016
(Article in Swedish) Rapidus: Xintela på väg till First North
March 13, 2024
Västra Hamnen Corporate Finance has published a research update for Q4 2023.
December 1, 2023
Västra Hamnen Corporate Finance has published an initial analysis of Xintela.
December 10, 2021
Edison Group has published a research update on Xintela.
July 14, 2021
Xintela, backed by its integrin biomarker technology platform XINMARK, is a potential disrupter
November 9, 2020
A status report of the Xintela has been published by Biostock
April 12, 2018
Read the full analysis here